Compare PRPO & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRPO | XLO |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.4M | 39.4M |
| IPO Year | 2000 | 2021 |
| Metric | PRPO | XLO |
|---|---|---|
| Price | $26.97 | $8.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 8.9K | ★ 319.7K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 35.03 | ★ 60.79 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,532,000.00 | $6,344,000.00 |
| Revenue This Year | N/A | $626.78 |
| Revenue Next Year | N/A | $79.08 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.95 | N/A |
| 52 Week Low | $4.90 | $0.46 |
| 52 Week High | $29.53 | $8.09 |
| Indicator | PRPO | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 53.64 | 92.44 |
| Support Level | $22.58 | $0.63 |
| Resistance Level | $28.76 | N/A |
| Average True Range (ATR) | 1.36 | 0.38 |
| MACD | -0.09 | 0.72 |
| Stochastic Oscillator | 46.83 | 97.01 |
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.